ReviewWorld journal of urology2022
Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies.
Review in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Variant histology in urothelial carcinoma: associated factors and survival impact after radical cystectomy.BMC urology · 2026Article
- Pathological assessment of morcellated tissue after ERBT: insights from a two-round Delphi survey.World journal of urology · 2026Article
- Development and validation of a multimodal AI-agent system for prognosis analysis of bladder urothelial carcinoma.NPJ precision oncology · 2026Article
- The Handling and Sampling of Radical Cystectomy Specimens: A Standardized Approach for Pathological Evaluation.Methods and protocols · 2025Review
- A histopathological snapshot of bladder cancer: a Johannesburg experience of 1480 histopathology reports.World journal of urology · 2025Observational
- Spontaneous Necrosis of a High-Risk Bladder Tumor Under Immunotherapy for Concurrent Malignant Melanoma: Role of BRAF Mutations and PD-L1 Expression.Biomedicines · 2025Article
- Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer.Insights into imaging · 2025Article
- Variation in cystectomy pathology reporting practice-results from an international survey of 212 pathologists.Virchows Archiv : an international journal of pathology · 2024Article
- The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature.Journal of clinical medicine · 2024Review
- Evaluation of magnetic resonance imaging for bladder cancer detection following transurethral resection of bladder tumour (TURBT).Abdominal radiology (New York) · 2024Article
- Bladder Cancer and Artificial Intelligence: Emerging Applications.The Urologic clinics of North America · 2024Review
- Analysis of postoperative complications in bladder cancer patients.Open medicine (Warsaw, Poland) · 2024Article
- Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective.Frontiers in oncology · 2023Review
- Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes.Surgical pathology clinics · 2022Review
- Article
- Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies.World journal of urology · 2022Review
- The 2022 ENCR Recommendations on recording and reporting of urothelial tumours of the urinary tract.Frontiers in oncology · 2022Article
- Under-reporting of carcinoma in situ in patients with high-grade papillary non-muscle-invasive bladder cancer.Bladder cancer (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimOptimal management of bladder cancer requires an accurate, standardised and timely pathological diagnosis, and close communication between surgeons and pathologists. Here, we provide an update on pathology reporting standards of transurethral resections of the bladder and cystectomies.
methodsWe reviewed recent literature, focusing on developments between 2013 and 2021.
resultsPublished reporting standards developed by pathology organizations have improved diagnosis and treatment. Tumor sub-staging and subtyping has gained increased attention. Lymph nodes continue to be an area of debate, and their staging has seen minor modifications. Several tasks, particularly regarding specimen preparation ("grossing"), are not yet standardized and offer opportunity for improvement. Molecular classification is rapidly evolving, but currently has only limited impact on management.
conclusionPathological reporting of bladder cancer is continuously evolving and remains challenging in some areas. This review provides an overview of recent major developments, with a particular focus on published reporting standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.